AZAHAR Study To Describe Anifrolumab in a Real-World Setting
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
152actual
Sites
13
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-03 | actual | When the study began enrolling |
| Primary completion | 2025-06-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-05 | actual | The whole study's end, after follow-up |
| First posted | 2024-10-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus (SLE)
Primary outcomes
what the primary-completion date above is the date OFSystemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score
measured At anifrolumab initiation, and every 6 months after anifrolumab initiation, up to 18 months.
Physician Global Assessment (PGA) score
measured At anifrolumab initiation, and every 6 months after anifrolumab initiation, up to 18 months.
Changes in SLEDAI-2K score
measured From anifrolumab initiation to 6, 12 and 18 months after anifrolumab initiation.
Changes in PGA score
measured From anifrolumab initiation to 6, 12 and 18 months after anifrolumab initiation.
Proportion of patients achieving low disease activity state
measured At anifrolumab initiation, and every 6 months after anifrolumab initiation, up to 18 months.
Proportion of patients achieving clinical remission
measured At anifrolumab initiation, and every 6 months after anifrolumab initiation, up to 18 months.
Publications
- PMID 39939126 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed